Tenet Healthcare (THC) research pages
- Tenet Healthcare Earnings and Financial History: Q2 2026 results in detail, segment-level adjusted EBITDA, hospital and ambulatory revenue drivers, full-year 2026 guidance, and the key metrics investors track each quarter
- Tenet Healthcare History: founded 1967 as National Medical Enterprises, renamed Tenet Healthcare in 1995, USPI acquisition and ambulatory strategy pivot, and the portfolio transformation that shaped the modern company
- Tenet Healthcare Investment Analysis: competitive position in U.S. healthcare services, USPI ambulatory moat, hospital portfolio quality, capital allocation framework, and bull, base, and bear scenarios
- Tenet Healthcare Stock History and Valuation: how to think about valuing a two-segment healthcare company, sum-of-the-parts framework, key valuation metrics, and scenario analysis
Quick answer
Tenet Healthcare Corporation (NYSE: THC) is a healthcare-services company in the Healthcare sector, specifically Healthcare Facilities and Services. The company operates two distinct businesses: a network of acute-care hospitals (Hospital Operations segment) and a large ambulatory surgery platform through USPI (Ambulatory Care segment). For investors, the central task is not to memorize a ticker or track short-term share price movements. It is to understand the economic logic of each segment, which variables determine margins and cash flow, why patients and payers choose these facilities, and what evidence would signal strengthening or weakening of the underlying business.
Direct answer: Tenet Healthcare's investment case rests on two economically distinct segments with different margins, growth rates, and risk profiles. The Ambulatory Care segment produced a 39.0% adjusted EBITDA margin in Q2 2026 and is the primary source of earnings quality. The Hospital Operations segment produced an 18.0% adjusted EBITDA margin in Q2 2026, improved from 15.6% a year earlier. Consolidated adjusted EBITDA reached $1.304 billion in Q2 2026, up 16.3%, and management raised full-year 2026 guidance to $4.83 to $5.03 billion. Near $3 billion in expected annual free cash flow supports a $2 billion share-repurchase expansion.
Company at a glance
| Item | Overview |
|---|---|
| Company | Tenet Healthcare Corporation |
| Ticker | THC (NYSE) |
| Sector | Healthcare |
| Industry | Healthcare Facilities and Services |
| Core customers | Patients, commercial insurers, Medicare, Medicaid, employers |
| Primary economic drivers | Hospital inpatient and outpatient volume and revenue per admission; ambulatory surgery center case volume, revenue per case, and EBITDA margin; payer mix; supplemental government payments |
| Key investor metrics | Ambulatory same-facility revenue and case growth; hospital adjusted admissions and revenue per adjusted admission; adjusted EBITDA by segment; adjusted free cash flow; payer mix; labor expense; debt and share repurchases |
| Major peer set | HCA Healthcare, Community Health Systems, Universal Health Services, LifePoint Health |
The table is intentionally qualitative. Market-sensitive figures such as share price, market capitalization, trailing multiples, and consensus estimates change continuously and should come from a timestamped market-data service rather than an evergreen article. This profile focuses on the business economics that change more slowly.
What does Tenet Healthcare actually do?
Tenet operates two distinctly structured healthcare businesses under one corporate entity, and understanding the difference between them is the starting point for all analysis.
Hospital Operations segment
The Hospital Operations segment owns and operates general-surgery and specialty acute-care hospitals in urban and suburban markets across the United States. These hospitals provide inpatient medical and surgical care, emergency services, intensive care, obstetrics, oncology, and a wide range of outpatient diagnostic and treatment services. Revenue is generated by billing insurers and government programs for facility services. The payer mix, which is the proportion of revenue from commercial insurers versus Medicare, Medicaid, and self-pay patients, is the primary determinant of margins because commercial rates are significantly higher than government reimbursement rates. In Q2 2026, Hospital Operations generated $4.240 billion in revenue, up 6% year over year, with adjusted EBITDA of $762 million and a margin of 18.0%, improved from 15.6% in the prior-year period.
Ambulatory Care segment (USPI)
The Ambulatory Care segment operates through USPI (United Surgical Partners International), one of the largest ambulatory surgery center networks in the United States. Ambulatory surgery centers (ASCs) and surgical hospitals perform elective outpatient procedures including orthopedic surgery, ophthalmology, gastrointestinal procedures, and general surgery, typically on a same-day basis without overnight hospitalization. The economics are structurally more attractive than hospital operations for two reasons: ASCs carry lower fixed-cost infrastructure than acute-care hospitals, and elective outpatient procedures attract a higher commercial payer mix because patients who choose elective surgery are more likely to have employer-sponsored or individual commercial insurance coverage. In Q2 2026, the Ambulatory Care segment generated $1.388 billion in revenue, up 9.3%, with adjusted EBITDA of $542 million and a 39.0% margin. Same-facility system-wide patient-service revenue grew 5.0%, driven by a 6.3% increase in net revenue per case as higher-acuity procedures and favorable service mix offset a 1.2% case volume decline.
The strategic logic is straightforward: as cases migrate from inpatient hospitals to lower-cost outpatient ambulatory settings, Tenet wants to capture that volume through USPI rather than cede it to independent surgery centers. This migration is a long-term structural trend in U.S. healthcare driven by advances in anesthesia and surgical technique, payer preference for lower-cost settings, and patient preference for convenience.
How Tenet Healthcare makes money
The two segments generate revenue through different mechanisms, and the quality of that revenue differs significantly.
Hospital economics
Hospital revenue is driven by adjusted admissions (a measure of total patient volume that converts outpatient visits to an inpatient equivalent) and revenue per adjusted admission (a measure of pricing and service intensity). Labor is the largest cost, typically representing 45 to 50 percent of net operating revenue in hospital operations. The balance between volume, price, and labor cost is the central operational challenge. Supplemental government payments, including Disproportionate Share Hospital (DSH) payments for serving low-income patients and Quality Improvement programs in certain states, can contribute meaningful revenue that may vary year to year based on policy changes. This supplemental-payment volatility is one reason investor models require judgment about the sustainability of any given quarter's hospital margin.
Ambulatory economics
ASC revenue per case is the key driver in the Ambulatory segment. Because outpatient elective surgery attracts commercial payers and avoids the emergency and indigent-care obligations of acute hospitals, revenue per case carries a structurally higher commercial mix. Fixed costs are lower per procedure at an ASC than at a hospital, which produces the wide margin differential observed in Q2 2026 (39.0% ambulatory versus 18.0% hospital). USPI typically operates surgery centers through joint ventures with health systems and physician groups, which aligns incentives and provides referral access. Tenet consolidates results for centers where it has majority ownership and reports them in Ambulatory Care adjusted EBITDA less noncontrolling interests (NCI) for segment-level analysis.
Capital allocation context
Tenet allocates capital across three uses: sustaining and growing the hospital portfolio, investing in new and acquired ambulatory surgery centers, and returning cash to shareholders. The Q2 2026 board decision to expand the share-repurchase authorization by $2 billion reflects management's view that the company generates more free cash flow than required for organic investment at current hospital and ASC valuations.
Key financial metrics (Q2 2026)
Tenet's Q2 2026 results provide a current snapshot of consolidated and segment performance. All figures are from the company's Q2 2026 earnings release.
| Metric | Q2 2026 | Year-over-year change |
|---|---|---|
| Net operating revenue (consolidated) | $5.628 billion | |
| Net income (available to common shareholders) | $826 million | |
| Diluted EPS (GAAP) | $9.84 | |
| Adjusted EPS | $6.12 | +52.2% |
| Consolidated adjusted EBITDA | $1.304 billion | +16.3% |
| Adjusted EBITDA margin (consolidated) | 23.2% | |
| Hospital Operations revenue | $4.240 billion | +6% |
| Hospital Operations adjusted EBITDA | $762 million | +22.3% |
| Hospital Operations adjusted EBITDA margin | 18.0% | vs. 15.6% prior year |
| Ambulatory Care revenue | $1.388 billion | +9.3% |
| Ambulatory Care adjusted EBITDA | $542 million | +8.8% |
| Ambulatory Care adjusted EBITDA margin | 39.0% | |
| Ambulatory same-facility system-wide revenue | +5.0% | |
| Ambulatory net revenue per case | +6.3% | |
| Ambulatory cases | -1.2% | |
| Full-year 2026 adjusted EBITDA guidance | $4.83 to $5.03 billion | Raised |
| Full-year 2026 adjusted free-cash-flow guidance | $2.725 to $3.025 billion | Raised |
| Share-repurchase authorization increase | $2 billion |
The most significant signal in Q2 2026 is the margin expansion in Hospital Operations, which moved from 15.6% to 18.0% adjusted EBITDA margin. That 240 basis point improvement on $4.2 billion in quarterly revenue represents roughly $100 million in additional quarterly EBITDA relative to the prior-year margin rate. The cause of that improvement, whether from favorable payer mix, supplemental payment timing, labor efficiencies, or a structural change in the hospital portfolio, is what analysts and investors should investigate by reading the full quarterly filing and earnings-call transcript.
Key risks
Healthcare services companies face a distinct set of risks compared to industrial or consumer businesses. The following table summarizes the most investor-relevant risk categories for Tenet.
| Risk | Description |
|---|---|
| Payer mix deterioration | A shift from commercial to Medicaid, Medicare, or self-pay patients reduces revenue per case and per admission. Commercial rates are typically 2 to 4 times Medicaid rates for the same procedure. |
| Labor inflation | Hospital staffing requires licensed nurses, physicians, and technicians. Contract labor (travel nurses) carries a premium cost and was a major margin headwind industry-wide in 2022 to 2023. A return of labor inflation would pressure hospital margins directly. |
| Government reimbursement policy | Annual Medicare and Medicaid rate-setting decisions by CMS (Centers for Medicare and Medicaid Services) can materially affect hospital revenue. DSH and supplemental-payment programs are subject to legislative and regulatory change. |
| Ambulatory case weakness | A slowdown in elective procedure volume would reduce revenue per period in the highest-margin segment. Causes could include macroeconomic pressure on elective spending, insurance coverage changes, or competitive shifts in case capture. |
| Acquisition integration | Tenet grows the USPI network partly through acquiring new surgery centers. Integration execution risk, overpayment risk, and the disruption of acquired center operations can temporarily impair margins. |
| Financial leverage | Healthcare companies typically carry meaningful long-term debt. High leverage reduces strategic flexibility in a downturn and increases refinancing risk when interest rates rise. |
| Compliance and legal exposure | Healthcare billing, coding, and regulatory compliance are complex. Government investigations, whistleblower suits under the False Claims Act, and state regulatory actions are recurring risks across the industry. |
| Supplemental-payment volatility | Supplemental government payments (DSH, quality programs, provider taxes) are a meaningful component of hospital margins. Their timing, amount, and continued availability can vary, making quarter-to-quarter comparisons difficult. |
What to watch each quarter
A disciplined investor can follow Tenet Healthcare with a focused scorecard rather than reacting to every headline. The following ten metrics cover the most important drivers across both segments.
| # | Metric | Why it matters |
|---|---|---|
| 1 | Ambulatory same-facility system-wide revenue | Measures organic growth in the highest-margin segment, stripping out acquisition effects |
| 2 | Ambulatory net revenue per case | Rising revenue per case indicates favorable payer mix and higher-acuity procedure mix; stagnation signals commoditization |
| 3 | Ambulatory adjusted EBITDA less NCI | The share of ambulatory earnings attributable to Tenet shareholders after noncontrolling interest; best measure of segment earnings quality |
| 4 | Hospital adjusted admissions | Volume health of the hospital network; sustained declines raise fixed-cost coverage concerns |
| 5 | Hospital revenue per adjusted admission | Captures pricing, payer mix, and service intensity in one figure |
| 6 | Hospital adjusted EBITDA margin | Shows whether labor and supply-cost management is translating into earnings |
| 7 | Commercial / Medicare / Medicaid payer mix | The primary determinant of reimbursement rates across both segments; deterioration in commercial mix is the most common source of hospital margin disappointment |
| 8 | Labor expense and contract labor | Labor is the largest cost in hospital operations; contract labor premiums directly reduce margins |
| 9 | Adjusted free cash flow | Cash available after maintenance and growth capital; the sustainable basis for buybacks, debt paydown, and acquisitions |
| 10 | Debt and share repurchases | Capital allocation priorities: is management reducing leverage, buying back stock at reasonable prices, or both? |
Frequently asked questions
What is Tenet Healthcare?
Tenet Healthcare Corporation (NYSE: THC) is a U.S. healthcare-services company built around two distinct economic engines: acute-care hospital operations and a large ambulatory-surgery platform through its USPI (United Surgical Partners International) joint ventures. The company operates general-surgery and specialty hospitals as well as hundreds of ambulatory surgery centers and surgical hospitals across the United States. Investors study it through the interaction of its two reporting segments, payer mix, reimbursement trends, labor costs, and capital allocation rather than through any single headline metric.
How does Tenet Healthcare make money?
Tenet generates revenue through two segments. The Hospital Operations segment earns fees for inpatient and outpatient care at acute-care hospitals, reimbursed by Medicare, Medicaid, commercial insurers, and self-pay patients. The Ambulatory Care segment, operated through USPI, earns facility fees for surgical procedures performed at outpatient surgery centers and surgical hospitals, where a favorable payer mix of commercial insurance produces materially higher margins than the hospital business. In Q2 2026 the Ambulatory segment produced a 39.0% adjusted EBITDA margin versus 18.0% for Hospital Operations.
What is Tenet Healthcare's ambulatory surgery business?
Tenet's ambulatory surgery platform operates through USPI (United Surgical Partners International), one of the largest ambulatory surgery center networks in the United States. In Q2 2026, the Ambulatory Care segment generated $1.388 billion in revenue, up 9.3% year over year, with adjusted EBITDA of $542 million and a 39.0% EBITDA margin. Same-facility system-wide patient-service revenue rose 5.0%, with net revenue per case up 6.3% as higher-acuity procedures and favorable service mix offset a 1.2% case volume decline. This segment produces Tenet's highest margins and is central to the long-term investment thesis.
What are the biggest risks for THC investors?
Major risks include payer mix deterioration (a shift from commercial to Medicaid or self-pay patients reduces revenue per case), labor inflation (contract labor costs are a persistent pressure in hospital operations), government reimbursement policy changes (Medicare and Medicaid rate updates can move the economics meaningfully), ambulatory case weakness (lower volumes hurt the high-margin segment most), acquisition integration risk, financial leverage, regulatory and compliance exposure, and supplemental-payment volatility. Investors should rank risks by probability, financial severity, and the company's ability to control them.
What does Tenet Healthcare's Q2 2026 financial performance show?
Tenet reported Q2 2026 net operating revenue of $5.628 billion and consolidated adjusted EBITDA of $1.304 billion, up 16.3% year over year, with an adjusted EBITDA margin of 23.2%. Adjusted EPS was $6.12, up 52.2%. Net income available to common shareholders was $826 million and diluted EPS was $9.84. Following the strong quarter, management raised full-year 2026 adjusted EBITDA guidance to $4.83 to $5.03 billion and adjusted free-cash-flow guidance to $2.725 to $3.025 billion. The board also increased the share-repurchase authorization by $2 billion.
Is Tenet Healthcare a hospital company or something broader?
Tenet is more than a traditional hospital operator. While its Hospital Operations segment (roughly 75% of total revenue) still dominates reported revenue, the Ambulatory Care segment through USPI now drives a disproportionate share of earnings given its 39% EBITDA margin versus 18% for hospitals. Management's stated strategy is to continue shifting the earnings mix toward higher-margin ambulatory care. The two businesses have different economic profiles, risk factors, and valuation frameworks, which is why investors should analyze each segment separately before forming a consolidated view.
What is the investment thesis for Tenet Healthcare (THC)?
The core bull case is that Tenet's ambulatory surgery platform through USPI continues to grow same-facility revenue and margin while the hospital portfolio generates improving margins from scale efficiencies and favorable payer mix. Near $3 billion in expected annual free cash flow supports share repurchases and debt reduction. The bear case centers on supplemental payment benefits not persisting, payer mix worsening, labor costs reaccelerating, and ambulatory case volumes remaining soft. The investment requires separate analysis of two economically distinct businesses rather than a single blended view.